These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3448761)

  • 1. Biochemical and immunologic diagnosis of cancer. Urinary immunocytology and bladder carcinomas.
    Arndt R; Huland H
    Tumour Biol; 1987; 8(2-3):105. PubMed ID: 3448761
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemical and immunologic diagnosis of cancer. Renal and transitional carcinomas.
    Cordon-Cardo C
    Tumour Biol; 1987; 8(2-3):94-102. PubMed ID: 3329405
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests?
    Pirtskalaishvili G; Konety BR; Getzenberg RH
    Postgrad Med; 1999 Nov; 106(6):85-6, 91-4. PubMed ID: 10576004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
    de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
    Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improvement of the determination of urinary tissue polypeptide antigen (TPA) and the clinical study in bladder cancer patients].
    Morimoto S; Yoshida M; Yasukawa S; Uekado Y; Yoshida T; Aoshi H; Ebisuno S; Ohkawa T
    Nihon Hinyokika Gakkai Zasshi; 1988 Dec; 79(12):1954-61. PubMed ID: 3230746
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer.
    Syrigos KN; Deonarian DP; Epenetos AA
    Hybridoma; 1999 Jun; 18(3):219-24. PubMed ID: 10475235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and immunologic diagnosis of cancer. Urinary bladder cancer.
    Paulie S
    Tumour Biol; 1987; 8(2-3):103-4. PubMed ID: 3448760
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: The BTA stat test is nonspecific for hematuria: an experimental hematuria model.
    Kinders RJ; Landicho H
    J Urol; 2002 Dec; 168(6):2556; author reply 2556-7. PubMed ID: 12441978
    [No Abstract]   [Full Text] [Related]  

  • 10. Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM.
    Bryan RT; Regan HL; Pirrie SJ; Devall AJ; Cheng KK; Zeegers MP; James ND; Knowles MA; Ward DG
    Br J Cancer; 2015 Mar; 112(6):1052-8. PubMed ID: 25719831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BTA test (Bard test) and urinary cytology].
    Fontaniere B; Ranchere D; Michot JP; Barfety-Michot B; Genna L; Charles N; Marechal JM; Colombel M
    Ann Pathol; 2000; 20 Suppl():S88-91. PubMed ID: 11261310
    [No Abstract]   [Full Text] [Related]  

  • 12. [Role of urinary cytology in the study of bladder cancer. Comparison with the BTA test].
    Iori F; De Matteis A; Frioni D; De Dominicis C; Leonardo C; Vahedi M; Laurenti C
    Arch Ital Urol Androl; 1999 Dec; 71(5):279-82. PubMed ID: 10673790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current diagnosis of superficial bladder cancer must be reconsidered.
    Zaak D; Hofstetter A
    Urol Int; 2002; 69(2):85-90. PubMed ID: 12187034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder cancer: Urinary EGFR and EpCAM predict cancer-specific survival.
    Sidaway P
    Nat Rev Urol; 2015 Apr; 12(4):184. PubMed ID: 25782173
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of exfoliated bladder cancer cells by monoclonal antibodies to tumor-associated cell surface antigens.
    Lin CW; Kirley SD; Khaw AH; Zhang DS; Prout GR
    J Occup Med; 1990 Sep; 32(9):910-6. PubMed ID: 2074518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A lively field of controversy].
    Böhle A; Jonas D
    Urologe A; 2003 Jul; 42(7):901. PubMed ID: 12959080
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
    Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
    J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of bladder cancer using telomerase activity in voided urine.
    Cheng CW; Chueh SC; Chern HD
    J Formos Med Assoc; 2000 Dec; 99(12):920-5. PubMed ID: 11155745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer.
    Golijanin D; Shapiro A; Pode D
    J Urol; 2000 Dec; 164(6):1922-5. PubMed ID: 11061882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.